Predictors for cancer treatment

• US 9,322,066 B2
• Filed: 08/08/2012
• Issued: 04/26/2016
• Est. Priority Date: 08/11/2011
• Status: Active Grant

• Current Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Original Assignee: Janssen Pharmaceutica NV (Johnson & Johnson)
• Inventors: Ricci, Deborah, Li, Weimin, Henitz, Erin DeVay
• Primary Examiner(s): Halvorson, Mark
• Application Number:
  US13/569,517
• Publication Number:
  US 20130216524A1
• Time in Patent Office: 1,357 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/19 Carboxylic acids, e.g. valproic acid salicylic acid A61K31/60
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/198 Alpha-amino acids, e.g. alanine or edetic acid [EDTA] betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00
• CPC Class Codes: A61K 31/573 substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• CPC Class Codes: A61K 31/69 Boron compounds
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: G01N 2800/52 Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/92 involving lipids, e.g. cholesterol , lipoproteins, or their receptors steroid hormones G01N33/743

Abstract

The present invention provides methods of predicting a response to a cancer treatment by determining CD68 level or PSMB1 (P11A) polymorphism in a biological sample and the presence or quantity of a second biomarker in the patient. The invention also provides kits and methods for treating cancer.

Claims

1. A method for predicting response to a cancer treatment comprising bortezomib and rituximab in a non-Hodgkin'"'"'s lymphoma cancer patient, comprising:

detecting the presence of a first predictor in a biological sample from said non-Hodgkin'"'"'s lymphoma cancer patient, wherein said first predictor is low CD68;

detecting the presence of a second predictor in said non-Hodgkin'"'"'s lymphoma cancer patient, wherein said second predictor is a PSMB1 (P11A) polymorphism comprising a C/G heterozygote;

wherein the presence of a biomarker pair comprising the low CD68 and the PSMB1 (P11A) polymorphism is correlated with at least one positive outcome; and

selecting the non-Hodgkin'"'"'s lymphoma cancer patients that have an increased chance for a favorable outcome to the cancer treatment comprising bortezomib and rituximab based on the presence of the biomarker pair comprising the first and second predictor; and

treating the selected non-Hodgkin'"'"'s lymphoma cancer patients with the cancer treatment comprising bortezomib and rituximab.

2. The method of claim 1, wherein low CD68 is 50% or less CD68-positive cells, as determined by immunohistochemistry.

3. The method of claim 1, wherein the non-Hodgkin lymphoma is follicular B-cell non-Hodgkin lymphoma.